CX3CL1 and osteoporosis: Administration of anti-CX3CL1 monoclonal antibodies has been shown to suppress the migration and differentiation of osteoclast precursor cells, reduce the number of mature osteoclasts, and markedly alleviate bone loss in ovariectomized (OVX) mouse models of osteoporosis.